Drug development crisis linked to bad technology choices, experts argue

Despite lower costs and increased speed of research inputs, the budget for getting a drug to market is soaring. Researchers suggest that a focus on process efficiency has favoured experimental models with less validity, more than outweighing efficency benefits. —> Read More